Clinical perspectives of bispecific antibodies in cancer

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 121-123

  De Gast, Gijsbert C ^a   Van De Winkel, Jan G J ^b   Bast, Bert E J E G ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD30 ANTIGEN; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN;

ANTIBODY SPECIFICITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; EFFECTOR CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, NEOPLASM; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS;

EID: 0030727725     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050412     Document Type: Review

References (19)

1. Canevari S, Stoter G, Arienti F et al. (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autonomous T lymphocytes retargeted by a specific monoclonal antibody. J Natl Cancer Inst 87:1463
2. De Gast GC, Haagen IA, Houten AA van et al. (1995) CD8 T cell activation after intravenous administration of CD3xCD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40:390
3. Demanet C, Brissinck J, Jonge J et al. (1996) Bispecific antibody-mediated immunotherapy of the BCL lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 87:4390
4. Deo YM, Graziano RF, Repp R, et al. (1997) Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today 18:127
5. Elsässer D, Valerius T, Repp R et al. (1996) HLA class II as potential target antigen on malignant B cells for therapy with bsAb in combination with granulocyte colony-stimulating factor. Blood 87:3803
6. Fanger NA, Wardwell K, Shen Lilian et al. (1996) Type I (CD64) and type II (CD32) Fcγ receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 157:541
7. Guyre PM, Graziano RF, Vance BA et al. (1989) Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 143: 1650
8. Hartmann F, Renner Ch, Jung W et al. (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89:2042
9. Kroesen BJ, Buter J, Sleijfer DT et al. (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70:652
10. Mack M, Riethmüller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021
11. Morton HC, Egmond v M, Winkel JGJ van de (1996) Structure and function of human IgA Fc receptors (FcαR). Crit Rev Immunol 16:423
12. Nitta T, Sato K, Yagita H et al. (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335:368
13. Renner C, Jung W, Sahin U, et al (1994) Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833
14. Riethmüller G, Schneider-Gadicke E, Schlimok G et al. (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinomas. Lancet 343:1177
15. Stockmeyer B, Valerius T, Repp R et al. (1996) Preclinical studies with FcγR bsAb and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57:697
16. Valerius T, Repp R, Wit TP de et al. (1 993) Involvement of the high-affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82:931
17. Valone FH, Kaufman PA, Guyre PM et al. (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the protooncogene Her-2/neu. J Clin Oncol 13:2281
18. Weiner GJ, Kostelny SA, Hillstrom JR et al. (1994) The role of T cell activation in anti-CD3 X antitumor bispecific antibody therapy. J Immunol 152:2385
19. Weiner LM, Clark JI, Davey M et al. (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erB-2 and FcγRIII. Cancer Res 55:4586